

Offene Studien Onkologie USB

COMPETE - A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with ¹⁷⁷Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somato-statin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).

NEUROENDOCRINE TUMORS, GEP-NET

Skyscraper-05 - A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Patients With Previously Untreated Locally Advanced Resectable Stage II, IIIA or Select IIIB NSCLC

LUNG CANCER, NSCLC, Stage II, resectable , Stage III, resectable

KEYNOTE-495 (MK3475-495): A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer

LUNG CANCER, NSCLC, Stage IV, 1st line, PD-L1 low, PD-L1 high, ECOG PS 0-1

TAK-788-3001 - A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of Mobocertinib (TAK-788) as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

LUNG CANCER, NSCLC, Stage IV, 1st line, PD-L1 low, PD-L1 high, EGFR Exon 20 Mutation, ECOG PS 0-1

SAKK 19/17 - First line durvalumab in patients with PD-L1 positive, advanced NSCLC with performance status 2 unsuitable for combination chemotherapy. A multicenter, single-arm phase II trial

LUNG CANCER, NSCLC, Stage IV, 1st line, PD-L1 high, ECOG PS 2

SKYSCRAPER-01 - A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

LUNG CANCER, NSCLC, Stage IV, 1st line, PD-L1 high, ECOG PS 0-1

CodeBreak 200 (AMGEN 20190009) - A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

LUNG CANCER, NSCLC, Stage IV, ≥ 2nd line, KRAS G12C

CheckMate 73L (CA209-73L) - A Phase 3, Randomized, Open Label Study to Compare Nivolumab + Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab + Ipilimumab or Nivolumab + CCRT followed by Nivolumab vs. CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)

LUNG CANCER, NSCLC, Stage III, non-resectable

ACHILES - A randomized phase II study comparing atezolizumab after concurrent chemoradiotherapy with chemoradiotherapy alone in limited disease small-cell lung cancer
LUNG CANCER, SCLC, Limited Disease

SAKK 16/18 - Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III(N2) non-small cell lung cancer (NSCLC). A multicenter phase II trial.
LUNG CANCER, NSCLC, Stage III, resectable

POLAR - A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer
BREAST CANCER, HR-positive, HER2-negative, 2nd line

IBCSG 55-17 (TOUCH) - To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)
BREAST CANCER, HR-positive, HER2-positive, neoadjuvant, elderly

CheckMate 7FL - Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL)
BREAST CANCER, HR-positive, HER2-negative, 1st line

KEYNOTE-859 (MK3475-859) - Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
GASTROINTESTINAL TUMORS, Gastric Cancer, 1st line

SAKK 41/16 - Neoadjuvant treatment with Regorafenib and Capecitabine combined with radiotherapy in locally advanced rectal cancer. A multicenter phase Ib trial (RECAP).
GASTROINTESTINAL TUMORS, Rectal Cancer, neoadjuvant

Basilea BZB-CS-301 - A pivotal study of derazantinib in patients with inoperable or advanced intrahepatic cholangiocarcinoma and FGFR2 fusions or FGFR2 gene mutations or amplifications (FIDES-01)
GASTROINTESTINAL TUMORS, Cholangiocarcinoma, FGFR2 mutation

BaseTIL - Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma (CA209-7H9)
MELANOMA, ≥2nd line

Imlygic (Amgen 20130193) - A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC® (Talimogene Laherparepvec) in Clinical Practice to Characterize the Risk of Herpetic Infection Among Patients, Close Contacts, and Health Care Providers; and Long-term Safety in Treated Patients
MELANOMA

MK7902-003 - A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants with Advanced Melanoma (LEAP-003)
MELANOMA, 1st line

HOVON 127 (SAKK 37/16) - Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma
LYMPHOMA, Burkitt Lymphoma, 1st line

HD21 - Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; in comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD
LYMPHOMA, Hodgkin Lymphoma, High grade, 1st line, elderly

KEYNOTE-676 - Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)
GENITOURINARY TUMORS, Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC)

SAG TCCS - Swiss Austrian German Testicular Cancer Cohort Study
REGISTER STUDIES, GENITOURINARY TUMORS, Germ Cell Tumors

CodeBreak 100 (AMGEN20170543) - A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation
VARIA / BASKET, Advanced Solid Tumor

IOV-COM 202 - A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors
VARIA / BASKET, Advanced Solid Tumor

CUPISCO (MX39795) - A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with cancer of unknown primary site who have received three cycles of platinum doublet chemotherapy
VARIA / BASKET, CARCINOMA OF UNKNOWN PRIMARY (CUP)

AMGEN 20190294 - A Non-interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Non-Small Cell Lung Cancer (NSCLC)
TRANSLATIONAL STUDIES